The move to Schedule III marks the greatest change to U.S. drug laws since 1970 and represents a new future for the $32 billion cannabis industry.

Shares of some cannabis firms fell between 3% and 12% at Thursday's close, erasing previous gains from the session, after U.S. President Donald Trump signed an executive order recommending the loosening of federal regulations on marijuana.

Boxing legend Mike Tyson celebrated President Donald Trump's executive order reclassifying marijuana from Schedule I to Schedule III drug status.

The drug is still not legal, but reclassifying cannabis to a Schedule III substance is expected to spark new innovation and investment.

U.S. President Donald Trump's move to relax marijuana regulations could ease some burden for cannabis companies, but will likely keep doors to access capital from big banks closed, experts said. Cannabis companies,

President Donald Trump has signed an executive order to move cannabis from Schedule I to Schedule III under the Controlled Substances Act

President Donald Trump signed an executive order that puts in motion the reclassification of marijuana as a Schedule III drug.

Cannabis companies like Tilray Brands and Canopy Growth could soon face a more mellow path ahead following President Donald Trump’s move to help reclassify the drug’s status.

The executive order would reclassify marijuana from a Schedule I to a less dangerous, Schedule III drug. Business leaders say the move is "long overdue" and it would open the door for more benefits for businesses and consumers.

U.S. President Donald Trump signed an executive order recommending the loosening of federal regulations on marijuana to reclassify it as a less dangerous drug.

Today, Dec. 18, 2025, investors are weighing Tilray’s fresh U.S. medical push and sector volatility after federal cannabis rescheduling.